Moffitt logo

COVID-19 Update: See the latest on our visitor policy here. Learn More

calledFromCancerPage=False - substr=
testProtocol=

Clinical Trials Search

Search Results:

Order By: 

Showing of 50

CLINICAL TRIAL 19873

A Phase II Open Label Single Arm Study of Adjuvant Nivolumab following Chemo-Radiation in localized Muscle-Invasive Bladder Cancer (NEXT)

Disease Site: Urinary Bladder

View Trial Details

CLINICAL TRIAL 19981

A Randomized Phase II Study of Atezolizumab (MPDL3280A) plus Recombinant Human IL-7 (CYT107) in patients with locally advanced or metastatic urothelial carcinoma

Disease Site: Urinary Bladder, Urothelial Cancer

View Trial Details

CLINICAL TRIAL 19988

A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy

Disease Site: Urothelial Cancer, Urinary Bladder

View Trial Details

CLINICAL TRIAL 20050

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination with ALT-803 in Patients with BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

Disease Site: Urinary Bladder

View Trial Details

CLINICAL TRIAL 20353

S1806, Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer

Disease Site: Urinary Bladder

View Trial Details

CLINICAL TRIAL 20840

An Exploratory, Open-label, Multicenter Phase 1b Trial to Evaluate Safety and Efficacy of Sym021 (Anti-PD-1) in Combination with Either Sym022 (Anti-LAG-3) or Sym023 (Anti-TIM-3) or Sym023 and Irinotecan in Patients with Recurrent Advanced Biliary Tract Carcinomas

Disease Site: Liver, Lung, Other Female Genital, Urinary Bladder

View Trial Details

CLINICAL TRIAL 20898

A Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE)

Disease Site: Any Site, Breast, Colorectal, Endometrial/Uterine, Extrapulmonary small cell lung cancer, Gallbladder, Gastric / Stomach, Gastrinoma, Gastrointestinal, Liver, Lung, Non small cell lung cancer, Other genitourinary, Other GI, Pancreas, Prostate, Reproductive System, Urinary Bladder, Uterus

View Trial Details

CLINICAL TRIAL 20943

Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients

Disease Site: Other Urinary, Urinary Bladder, Urothelial Cancer

View Trial Details

CLINICAL TRIAL 20964

A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations

Disease Site: Brain and Nervous System, Breast, Ill-Defined Sites, Lung, Other Digestive Organ, Urinary Bladder, Brain metastasis, Leptomeningeal (LMD)

View Trial Details

CLINICAL TRIAL 21080

A Phase 1, Open-Label, Dose-Escalation, and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SRK-181 Administered Alone or in Combination with a Checkpoint Inhibitor in Patients with Locally Advanced or Metastatic Solid Tumors (DRAGON)

Disease Site: Any Site, Lung, Melanoma, skin, Urinary Bladder

View Trial Details

CLINICAL TRIAL 21180

A First-in-Human, Two-Part, Open-Label, Clinical Study to Assess the Safety, Tolerability and Activity of Intravenous Doses of ICT01 as Monotherapy and in Combination with an Immune Checkpoint Inhibitor, in Patients with Advanced-Stage, Relapsed/Refractory Cancer (EVICTION Study)

Disease Site: Any Site, Breast, Colon, Larynx, Leukemia, other, Lip, Oral Cavity and Pharynx, Lung, Melanoma, skin, Ovary, Prostate, Stomach, Urinary Bladder

View Trial Details

CLINICAL TRIAL 90015

Phase 1 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies

Disease Site: Breast, Lung, Melanoma, skin, Ovary, Pancreas, Urinary Bladder

View Trial Details
;